Sean McCutcheon
Stock Analyst at Raymond James
(0.27)
# 4,281
Out of 4,981 analysts
10
Total ratings
22.22%
Success rate
-17.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean McCutcheon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Assumes: Strong Buy | $72 | $46.20 | +55.84% | 1 | Sep 12, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $4.79 | +150.52% | 1 | Jul 11, 2025 | |
| JANX Janux Therapeutics | Initiates: Outperform | $65 | $23.56 | +175.89% | 1 | Jul 11, 2025 | |
| CMPX Compass Therapeutics | Reinstates: Outperform | $9 | $3.69 | +143.90% | 1 | Jul 1, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Outperform | $11 | $3.19 | +244.83% | 1 | Jul 1, 2025 | |
| ENGN enGene Holdings | Initiates: Outperform | $23 | $5.71 | +302.80% | 1 | Nov 27, 2024 | |
| XNCR Xencor | Maintains: Strong Buy | $58 → $40 | $8.49 | +371.14% | 1 | Jun 14, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $92 → $70 | $49.44 | +41.59% | 2 | May 23, 2024 | |
| LEGN Legend Biotech | Initiates: Outperform | $86 | $33.88 | +153.84% | 1 | Mar 13, 2024 |
Revolution Medicines
Sep 12, 2025
Assumes: Strong Buy
Price Target: $72
Current: $46.20
Upside: +55.84%
Vir Biotechnology
Jul 11, 2025
Initiates: Outperform
Price Target: $12
Current: $4.79
Upside: +150.52%
Janux Therapeutics
Jul 11, 2025
Initiates: Outperform
Price Target: $65
Current: $23.56
Upside: +175.89%
Compass Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $9
Current: $3.69
Upside: +143.90%
Black Diamond Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $11
Current: $3.19
Upside: +244.83%
enGene Holdings
Nov 27, 2024
Initiates: Outperform
Price Target: $23
Current: $5.71
Upside: +302.80%
Xencor
Jun 14, 2024
Maintains: Strong Buy
Price Target: $58 → $40
Current: $8.49
Upside: +371.14%
Cytokinetics
May 23, 2024
Maintains: Outperform
Price Target: $92 → $70
Current: $49.44
Upside: +41.59%
Legend Biotech
Mar 13, 2024
Initiates: Outperform
Price Target: $86
Current: $33.88
Upside: +153.84%